Drug of Abuse panel- 6 Drugs By Rapid

Blood

Report in 4Hrs

At Home

No Fasting Required

Details

Rapid urine/blood screening panels.

₹932₹1,332

30% OFF

Drug of Abuse Panel - 6 Drugs By Rapid: Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Overview: This rapid screening test detects the presence of six commonly abused drugs or their metabolites in biological samples (typically urine, saliva, or blood). The panel uses immunoassay technology for quick, preliminary drug detection.
- Six Drugs Detected: Amphetamines (including methamphetamine), Benzodiazepines, Cocaine, Marijuana (THC), Opioids (morphine/codeine), and Phencyclidine (PCP)
- Primary Indications for Testing:
  - Pre-employment drug screening and workplace drug testing programs
  - Court-ordered drug testing and legal proceedings
  - Monitoring patients on substance abuse treatment programs
  - Emergency department evaluation for suspected acute drug intoxication
  - Investigation of altered mental status or unexplained behavioral changes
  - Sports and athletic event drug screening
  - Pain management monitoring for patients on opioid therapy
  - Child welfare and custody evaluations
- Typical Timing: Can be performed immediately when indicated; results typically available within 5-15 minutes depending on the specimen type and laboratory setting
Section 2: Normal Range
- Result Interpretation:
  - NEGATIVE Result: No drugs detected or levels below the detection cutoff threshold. This is the normal/expected result, indicating the six tested substances are not present in clinically significant amounts.
  - POSITIVE Result: One or more drugs detected at or above the cutoff concentration. This indicates the presence of the substance(s) in the sample.
- Cutoff Thresholds (Typical Values - urine):
  - Amphetamines: 500-1000 ng/mL (nanograms per milliliter)
  - Benzodiazepines: 200-300 ng/mL
  - Cocaine: 150-300 ng/mL
  - Marijuana (THC): 50-150 ng/mL
  - Opioids: 300-2000 ng/mL
  - PCP: 25-75 ng/mL
- Units of Measurement: ng/mL (nanograms per milliliter) for urine; results typically reported as qualitative (positive/negative) for rapid screening panels
- Borderline/Invalid Results: Results very close to the cutoff or invalid specimens may require confirmation by more sensitive laboratory methods such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS)
Section 3: Interpretation
- Positive Results - Individual Drug Implications:
  - Amphetamines Positive: May indicate recent use of methamphetamine, amphetamine, or related stimulants; can also result from prescribed medications (pseudoephedrine, phentermine); timing depends on dose and individual metabolism (detectable 1-3 days)
  - Benzodiazepines Positive: Indicates use of benzodiazepines (diazepam, alprazolam, lorazepam); may be prescribed or illicit use; detectable for 3-6 weeks depending on specific agent and individual factors
  - Cocaine Positive: Indicates recent cocaine use (drug or metabolite); detectable for 2-4 days; primarily illicit use unless in very rare medical contexts
  - Marijuana (THC) Positive: Indicates cannabis use (legal or illegal depending on jurisdiction); detectable for 3-30 days depending on frequency of use and individual metabolism; can appear positive from passive smoke exposure in some cases
  - Opioids Positive: Indicates use of morphine, codeine, or heroin; can be from prescribed pain medications or illicit use; detectable for 2-4 days; may require confirmation to distinguish prescribed from illicit use
  - PCP Positive: Indicates phencyclidine use; primarily illicit drug; detectable for 1-8 days; associated with significant behavioral and psychiatric effects
- Factors Affecting Test Results:
  - Time since drug use/administration - critical factor in detectability
  - Individual metabolism and kidney function - affects drug elimination
  - Frequency and quantity of use - chronic users may show positive longer
  - Cross-reactivity - some substances may produce false positives (e.g., cold medications with amphetamines)
  - Sample collection and handling - improper technique can affect results
  - Specimen type (urine vs. saliva vs. blood) - affects detection window
  - Prescription medications that may cause positive results
- Clinical Significance of Results:
  - Rapid screening results are preliminary and presumptive; positive results typically require confirmation by more specific testing
  - False positives can occur due to cross-reactivity or contaminants
  - Cannot determine level of impairment or quantify drug concentration with rapid testing
  - Negative result does not rule out drug use if tested outside detection window
  - Multiple positive results may indicate polydrug use or abuse pattern
Section 4: Associated Organs
- Primary Organ Systems Affected by Abused Drugs:
  - Central Nervous System (CNS): All six drug categories directly affect brain function; stimulants (amphetamines, cocaine) increase alertness and dopamine; depressants (benzodiazepines, opioids) slow CNS activity; PCP causes dissociation
  - Cardiovascular System: Stimulants (amphetamines, cocaine) elevate heart rate and blood pressure; opioids can cause hypotension; increased risk of arrhythmias, myocardial infarction, and stroke
  - Respiratory System: Opioids and benzodiazepines suppress respiratory drive; THC and cocaine smoking cause respiratory irritation; acute respiratory depression risk with overdose
  - Liver: Primary site of drug metabolism; chronic use increases liver damage risk; hepatitis transmission risk with injection drug use
  - Kidneys: Responsible for drug excretion in urine; chronic use may impair function; dehydration and rhabdomyolysis risk with stimulant overdose
- Medical Conditions Associated with Positive Results:
  - Substance use disorder (addiction)
  - Acute intoxication or overdose
  - Withdrawal syndromes
  - Polydrug use and drug interactions
  - Psychiatric disorders (anxiety, depression, psychosis)
  - Infection-related complications (HIV, hepatitis C from needle sharing)
- Potential Complications and Risks:
  - Stimulants (Amphetamines/Cocaine): Myocardial infarction, stroke, seizures, hyperthermia, psychosis, sudden cardiac death
  - Depressants (Benzodiazepines/Opioids): Respiratory depression, overdose, death (especially with polydrug use), dependency, withdrawal seizures
  - PCP: Violent behavior, seizures, rhabdomyolysis, acute kidney injury, hyperthermia, death
  - THC: Cannabis hyperemesis syndrome, acute psychosis, amotivational syndrome, impaired driving ability
Section 5: Follow-up Tests
- Confirmatory Testing:
  - Gas Chromatography-Mass Spectrometry (GC-MS): Gold standard confirmation test for any positive rapid screening result; provides specific identification and quantitative levels
  - Liquid Chromatography-Mass Spectrometry (LC-MS/MS): Alternative confirmatory method; highly specific and sensitive; can detect metabolites and distinguish active drug from inactive metabolites
  - High-Performance Liquid Chromatography (HPLC): Additional option for confirmation of specific substances; quantifies exact drug concentration
- Extended Drug Panel Testing:
  - Expanded panels testing for additional drugs (synthetic cannabinoids, bath salts, fentanyl, tramadol, methadone) if polydrug use suspected
  - Synthetic opioid panels for detection of fentanyl and derivatives
  - Alcohol testing (ethanol, EtG, EtS) if alcohol use evaluation needed
- Associated Diagnostic Tests:
  - Comprehensive Metabolic Panel (CMP) - assess kidney and liver function
  - Complete Blood Count (CBC) - evaluate for infections or blood abnormalities
  - Liver Function Tests (LFTs) - specifically assess hepatic function
  - Infectious Disease Serology - HIV, Hepatitis B and C testing if injection drug use suspected
  - Electrocardiogram (ECG) - evaluate cardiac effects of stimulants or opioids in overdose cases
  - Urinalysis - assess for complications and screen for other substances
- Monitoring and Follow-up Frequency:
  - Substance Abuse Treatment Programs: Typically monthly or more frequent random testing (weekly to bi-weekly); more frequent in early treatment phases
  - Workplace Programs: Random testing varies by employer policy; typically annually or per employment contract
  - Legal/Court-Ordered: Frequency determined by court order; often monthly or per probation requirements
  - Medical Monitoring: For patients on opioid therapy, periodic testing (quarterly to semi-annually) per pain management protocols
Section 6: Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for this test
- Sample Collection Specifications:
  - Urine Sample: Typically 30-45 mL collected in sterile container; mid-stream clean catch preferred; no fasting needed; can be collected at any time of day
  - Saliva Sample: No food or drink 10-15 minutes before collection; no fasting restriction; approximately 1 mL collected using absorbent collection device
  - Blood Sample: Venipuncture collection in appropriate tube (typically serum separator); no fasting required; can be collected any time
- Special Patient Preparation Instructions:
  - Inform healthcare provider of all prescription medications being taken (may affect test interpretation)
  - No special diet restrictions necessary
  - Maintain normal hydration (adequate water intake) to ensure adequate sample volume, especially for urine collection
  - For supervised collection: arrive with empty bladder if urine sample requested (for DOT-compliant testing)
  - For legally-witnessed testing: photo identification required
  - Disclose use of over-the-counter medications that may contain testable substances (cold medications, pain relievers containing pseudoephedrine)
- Medications That May Affect Results:
  - May Cause False Positive for Amphetamines: Pseudoephedrine, phentermine, ephedrine, some decongestants, methylphenidate, bupropion
  - May Cause False Positive for PCP: Dextromethorphan (DXM - in cough medicine), tramadol, venlafaxine
  - May Cause False Positive for THC: NSAIDs (ibuprofen, naproxen), some hemp seed products
  - May Affect Opioid Results: Poppy seed consumption, prescribed opioids (codeine, morphine, hydrocodone)
- Important Patient Considerations:
  - This test cannot assess impairment level or determine when drug was used
  - Rapid screening results are preliminary; positive results require confirmation with more specific testing
  - Chain of custody protocols must be followed for legal or court-ordered testing
  - Test results are confidential and subject to privacy regulations (HIPAA)

How our test process works!